Nephrocare Health Services will host an analyst and institutional investor meeting on August 18, 2026, at the Grand Hyatt in Mumbai. The company disclosed the schedule under Regulation 30(6) read with Schedule III of the SEBI Listing Regulations, 2015.

The conference is scheduled to begin at 11:00 am IST. Company officials will participate in both group and one-on-one sessions with market participants. The disclosure was issued by Kishore Kathri, Company Secretary and Head Legal, on August 13, 2026.

Meeting Details

The interaction is part of the company’s regular engagement with investors. Key details of the scheduled event are outlined below:

Disclosure Compliance

Nephrocare Health Services stated that all discussions during the meet will be based on publicly available information. The company confirmed that no unpublished price sensitive information (UPSI) is intended to be discussed during these interactions.

The intimation is available on the company’s website. The disclosure noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Nephrocare Health Services expanded its international footprint with the acquisition of dialysis center assets in the Philippines. The company’s overseas step-down wholly-owned subsidiary, Nephrocare Health Care Services Philippines Inc., entered into an Asset Transfer Agreement dated August 12, 2026, to purchase identified assets from Juan Nephro Dialysis Center.

The transaction value stands at PhP 71,800,000 (Philippine Pesos Seventy-One Million Eight Hundred Thousand Pesos Only). The acquired assets relate to a dialysis center located in Davao City, Davao Del Sur, Philippines.

Transaction Details

The deal was structured as an asset purchase rather than a share acquisition. According to the disclosure made to stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, there are no special rights attached to the agreement, such as director appointments or subscription rights.

The seller is not related to the promoter group or group companies of Nephrocare Health Services. Consequently, the transaction does not fall within the scope of related-party transactions and was executed at arm’s length.

Regulatory Disclosure

Nephrocare Health Services Limited issued the disclosure pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that no shares were issued as part of this agreement, and no loan facilities were involved in the transaction structure.